Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by COLIN P DINNEY and BOGDAN A CZERNIAK.
COLIN P DINNEY
Connection Strength
5.671
BOGDAN A CZERNIAK
  1. Focus on bladder cancer. Cancer Cell. 2004 Aug; 6(2):111-6.
    View in: PubMed
    Score: 0.246
  2. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. Cell Rep. 2024 May 28; 43(5):114146.
    View in: PubMed
    Score: 0.241
  3. Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping. Res Sq. 2024 Apr 10.
    View in: PubMed
    Score: 0.240
  4. Erratum: The origin of bladder cancer from mucosal field effects. iScience. 2022 Jul 15; 25(7):104715.
    View in: PubMed
    Score: 0.213
  5. Lentiviral interferon: A novel method for gene therapy in bladder cancer. Mol Ther Oncolytics. 2022 Sep 15; 26:141-157.
    View in: PubMed
    Score: 0.212
  6. The origin of bladder cancer from mucosal field effects. iScience. 2022 Jul 15; 25(7):104551.
    View in: PubMed
    Score: 0.212
  7. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020 06 16; 10(1):9743.
    View in: PubMed
    Score: 0.184
  8. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
    View in: PubMed
    Score: 0.184
  9. TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Mol Cancer Res. 2020 06; 18(6):811-821.
    View in: PubMed
    Score: 0.181
  10. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
    View in: PubMed
    Score: 0.171
  11. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 02 19; 26(8):2241-2256.e4.
    View in: PubMed
    Score: 0.168
  12. Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus. 2019 07; 5(4):664-675.
    View in: PubMed
    Score: 0.157
  13. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583.
    View in: PubMed
    Score: 0.151
  14. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget. 2017 May 23; 8(21):34205-34222.
    View in: PubMed
    Score: 0.149
  15. Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017 01 19; 7:40714.
    View in: PubMed
    Score: 0.146
  16. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016 Oct; 12:105-117.
    View in: PubMed
    Score: 0.142
  17. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620.
    View in: PubMed
    Score: 0.137
  18. Origins of Bladder Cancer. Annu Rev Pathol. 2016 05 23; 11:149-74.
    View in: PubMed
    Score: 0.137
  19. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):377-94, x-xi.
    View in: PubMed
    Score: 0.129
  20. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol. 2014 Nov; 32(8):1108-15.
    View in: PubMed
    Score: 0.125
  21. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7.
    View in: PubMed
    Score: 0.114
  22. Detection of bladder cancer using proteomic profiling of urine sediments. PLoS One. 2012; 7(8):e42452.
    View in: PubMed
    Score: 0.107
  23. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol. 2010 Jul-Aug; 28(4):429-40.
    View in: PubMed
    Score: 0.092
  24. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct; 40(10):1448-52.
    View in: PubMed
    Score: 0.086
  25. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst. 2008 Oct 01; 100(19):1401-11.
    View in: PubMed
    Score: 0.082
  26. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 2008 Jul; 88(7):694-721.
    View in: PubMed
    Score: 0.080
  27. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008 Jan; 179(1):353-8.
    View in: PubMed
    Score: 0.077
  28. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9.
    View in: PubMed
    Score: 0.076
  29. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest. 2005 Apr; 85(4):532-49.
    View in: PubMed
    Score: 0.064
  30. Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. Nat Commun. 2024 Aug 02; 15(1):6538.
    View in: PubMed
    Score: 0.061
  31. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004 Feb; 171(2 Pt 1):570-4.
    View in: PubMed
    Score: 0.059
  32. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.058
  33. Combined Mek inhibition and Pparg activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced Carcinogenesis. bioRxiv. 2023 Aug 21.
    View in: PubMed
    Score: 0.057
  34. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
    View in: PubMed
    Score: 0.054
  35. Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer. Mol Ther Methods Clin Dev. 2021 Sep 10; 22:360-376.
    View in: PubMed
    Score: 0.049
  36. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 09; 206(3):548-557.
    View in: PubMed
    Score: 0.049
  37. Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urol Oncol. 2021 05; 39(5):301.e17-301.e28.
    View in: PubMed
    Score: 0.048
  38. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep. 2001 Jan-Feb; 8(1):9-15.
    View in: PubMed
    Score: 0.048
  39. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol. 2020 07 07; 154(2):208-214.
    View in: PubMed
    Score: 0.046
  40. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5. Eur Urol. 2020 04; 77(4):436-438.
    View in: PubMed
    Score: 0.045
  41. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 06; 37(6):354.e19-354.e26.
    View in: PubMed
    Score: 0.042
  42. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenetics. 2018; 10:71.
    View in: PubMed
    Score: 0.040
  43. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65.
    View in: PubMed
    Score: 0.040
  44. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol. 2017 09; 67:126-133.
    View in: PubMed
    Score: 0.038
  45. Targeting EGFR in bladder cancer. World J Urol. 2007 Dec; 25(6):573-9.
    View in: PubMed
    Score: 0.038
  46. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506.
    View in: PubMed
    Score: 0.037
  47. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget. 2016 Dec 06; 7(49):80164-80174.
    View in: PubMed
    Score: 0.036
  48. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691.
    View in: PubMed
    Score: 0.036
  49. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. Medicine (Baltimore). 2016 Aug; 95(31):e4500.
    View in: PubMed
    Score: 0.035
  50. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62.
    View in: PubMed
    Score: 0.033
  51. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14.
    View in: PubMed
    Score: 0.033
  52. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
    View in: PubMed
    Score: 0.031
  53. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34.
    View in: PubMed
    Score: 0.031
  54. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014 Jul; 11(7):400-10.
    View in: PubMed
    Score: 0.030
  55. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72.
    View in: PubMed
    Score: 0.030
  56. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65.
    View in: PubMed
    Score: 0.030
  57. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 2013 Jul; 12(7):1245-54.
    View in: PubMed
    Score: 0.028
  58. The p63 protein isoform ?Np63a inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 2013 Feb 01; 288(5):3275-88.
    View in: PubMed
    Score: 0.027
  59. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013 May; 189(5):1656-61.
    View in: PubMed
    Score: 0.027
  60. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010 Nov; 42(11):978-84.
    View in: PubMed
    Score: 0.024
  61. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer. 2010 Jan 15; 116(2):340-6.
    View in: PubMed
    Score: 0.022
  62. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet. 2009 Sep; 41(9):991-5.
    View in: PubMed
    Score: 0.022
  63. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol. 2007 Jan-Feb; 25(1):38-45.
    View in: PubMed
    Score: 0.018
  64. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006 Aug 01; 12(15):4671-7.
    View in: PubMed
    Score: 0.018
  65. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 2006 Mar; 67(3):466-71.
    View in: PubMed
    Score: 0.017
  66. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther. 2002 Aug; 9(8):687-91.
    View in: PubMed
    Score: 0.013
  67. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 1997 Oct 01; 39(3):687-95.
    View in: PubMed
    Score: 0.010
  68. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology. 1996 Mar; 47(3):305-10.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.